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INTRODUCTION 
 
“When the hair becomes grey and scant, when specks of earthly 
matter begin to be deposited in the tunics of artery, and when there is 
formed a white zone around the cornea, at the same time, I dare say 
invariably the prostate increases in volume”. 
- Sir Benjamin Brodie. 
The prostate is a pear shaped glandular retroperitoneal organ 
encircling the neck of the bladder and urethra. It weighs about 20 gram in 
normal adult male. The prostate is a functional conduit that allows urine to 
pass from the urinary bladder to the urethra, and adds nutritional secretions 
to the sperm to form semen during ejaculation. Prostatic secretion 
contributes 20% of total volume of semen. It includes spermine, citric 
acid, cholesterol, phospholipids, fibrinolysin, fibrinogenase, zinc and acid 
phosphatase. 
Prostatic diseases, benign and malignant are collectively responsible 
for significant morbidity and mortality in men throughout the world. The 
ability of this small gland to cause misery for aging male as a consequence 
of bladder obstruction is astonishing. 
  
Only three pathologic processes affect the prostate gland with 
sufficient frequency to merit discussion namely inflammation, benign 
prostatic hyperplasia (BPH) and tumours.  
Inflammation of prostate is called as prostatitis. Prostatitis may be 
divided into several categories such as acute bacterial prostatitis, chronic 
bacterial prostatitis, chronic abacterial prostatitis and granulomatous 
prostastitis. 
Benign prostatic hyperplasia (BPH) is an extremely common 
disorder in men over age 50.
77
 It is characterized by hyperplasia of 
prostatic stromal and epithelial cells, resulting in the formation of large, 
fairly discrete nodules in the periurethral region of the prostate. 
Prostate cancer is now the sixth most common cancer in the world
92
. 
Prostatic adenocarcinoma is the second most common cause of cancer 
mortality in men next to lung cancer. When the terms "prostate cancer" 
or "prostate adenocarcinoma" are used without qualifications it refers to 
the common or acinar variant of prostate cancer. In approximately 70% of 
cases, carcinoma of the prostate arises in the peripheral zone of the gland, 
classically in a posterior location, where it may be palpable on rectal 
examination. 
  
Prostatic cancers are diagnosed by fine needle aspiration cytology, 
needle biopsies, transurethral resection of prostate (TURP) and 
prostatectomy. 
  Interpretation of prostatic biopsies has been a continuous problem 
for practising pathologist. Various types of difficulties have been 
encountered while diagnosing and typing prostatic carcinoma and 
premalignant lesions especially in TURP chips where there is loss of 
orientation and coagulation of tissue during cauterization. 
Prostatic lesions on routine haematoxylin & eosin staining 
sometimes cause diagnostic dilemma between benign and malignant 
lesions and especially in premalignant lesions like atypical adenomatous 
hyperplasia (AAH) and prostatic intraepithelial neoplasia (PIN). An 
important diagnostic criteria in the differentiation is the loss of basal cell 
layer in adenocarcinoma and its presence in the benign lesions. Several 
immunohistochemical markers have been used to stain the basal cells of 
prostate like High molecular weight cytokeratin (HMWCK), p63 etc. 
Proliferative markers like silver staining nucleolar organizer regions 
(AgNOR), proliferating cell nuclear antigen (PCNA) are of great help in 
differentiating benign premalignant and malignant lesions. 
  
 This current study aims at analysis of histopathological features of 
various non neoplastic and neoplastic lesions of the prostate including the 
grading of malignant lesions and evaluation of role of basal cell markers 
and proliferative markers in different benign, premalignant and malignant 
lesions of prostate.  
Histological typing, grading and staging of prostatic carcinoma are 
vital in planning the treatment strategies and predicting the survival rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
AIM OF THE STUDY 
 
1. To study the incidence of various prostatic lesions in and around Madurai 
during the period from May 2009 to July 2011. 
2. To analyse the age incidence of various prostatic lesions. 
3. To study the histopathology of non neoplastic and neoplastic lesions of 
prostate. 
4. To categorize the prostatic malignancy and to apply Gleason grading 
system for prostatic carcinoma. 
5. To study and compare the role of proliferative marker such as AgNOR and 
immunohistochemical prostatic basal cell marker such as p63 in different 
benign, premalignant and malignant lesions of prostate. 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
 
EMBRYOLOGY 
The prostate gland is formed from the upper part of the definitive 
urogenital sinus. The buds that arise from the mesodermal part of prostatic 
urethra form the inner glandular zone. The buds that arise from rest of the 
prostatic urethra (endoderm) form the outer glandular part.  
Development and growth of prostate is androgen dependent and  
5α reductase is the essential androgen for prostate development.24 
 
 
Figure 1: Location of prostate gland 
  
 
 
  
ANATOMY  
The first description of the anatomy of prostate dates back to third 
century. B.C. Heterophilus is credited with being the first to provide 
anatomic description of prostate.  
The prostate is a pyramidal shaped fibro muscular gland which 
surrounds the prostatic urethra from the bladder base to membranous 
urethra (Figure 1). The adult prostate weighs approximately 20gm, 
measures 3cm in length, 4cm in width, and 2cm in diameter.
37
 
The human prostate is a composite organ, made up of glandular and 
non glandular components. 
Glandular component 
The anatomical features and developmental biology of the prostate 
have been explored over the past decades by Mc Neal JE.
51 
He described 
zonal anatomy of prostate based on examination of gland in different 
planes of section.
51, 52
 
Zonal anatomy (Figure 2) 
   The glandular tissue may be subdivided into three distinct zones
24
: 
 Transition zone - 5 % of volume, chief source of nodular hyperplasia, 
and 15-20% of carcinomas. 
 Central zone - 25% of volume, 10% carcinomas. 
 Peripheral zone -70% of Volume, 70-75% of Carcinomas. 
  
 
 
Figure 2: Zonal anatomy of prostate gland 
Non glandular component 
It is concentrated anteriomedially and responsible for anterior convexity 
of the organ. It includes 
 Preprostatic sphincter 
 Anterior fibromuscular stroma 
 Prostatic capsule 
HISTOLOGY :( Figure 3) 
The prostate is composed of glandular epithelium and fibromuscular 
stroma. The glands are tubuloalveolar type. The glands are lined by three 
distinct epithelial cell populations such as secretory, basal, and 
  
neuroendocrine cells. The secretory cells are terminally differentiated 
columnar cells and stain with prostate specific antigen (PSA) and prostatic 
acid phosphatase (PAP). Basal cells are peripherally located between the 
secretory cells and basement membrane. They stain for high molecular 
weight cytokeratin.
18 
Neuroendocrine cells are irregularly distributed 
throughout the ducts and acini. These are difficult to recognize without 
special stains. Most of them contain serotonin and less frequently 
calcitonin, somatostatin or human chorionic gonadotrophin hormone. 
Corpora amylacea are laminated calcified eosinophilic inspissated 
secretions present within the lumina of the glands.  
 
Figure 3: Normal histology of prostate 
 
 
  
Arteries   
The prostate is supplied by branches from the inferior vesical, 
internal pudendal and middle rectal arteries.
37
 
Veins 
 Prostatic vein drains into the prostatic plexus which empties into the 
internal iliac vein.
37
 
Lymphatic drainage  
 Lymphatics from the prostate drains into the internal iliac nodes, 
some of them drain into external iliac and sacral lymph nodes.
37
 
Innervation   
       The prostate has an abundant nerve supply from the inferior 
hypogastric (pelvic) plexus.
37
 
PATHOLOGY OF PROSTATE 
 Pathological lesions of prostate are categorized into non neoplastic 
and neoplastic lesions. Nonneoplastic lesions are ectopia, benign prostatic 
hyperplasia (BPH), prostatitis, infarction, calculi and cystic lesions. 
Tumour like lesions include postoperative spindle cell nodule and 
inflammatory pseudotumour. Neoplastic lesions include benign and 
malignant epithelial tumours, mesenchymal tumours and secondary 
tumours. Among these the following lesions are common  
  
 Inflammatory lesions 
 Benign prostatic hyperplasia (BPH) 
 Prostatic adenocarcinoma 
I. NONNEOPLASTIC LESIONS 
 INFLAMMATORY LESIONS OF PROSTATE  
     Inflammatory lesions of prostate are known as prostatitis. They are 
classified into Common and uncommon types.
24
 
Common types 
  Acute bacterial prostatitis 
  Chronic bacterial prostatitis  
  Non bacterial prostatitis 
  Prostatodynia 
Uncommon types 
  Gonococcal prostatitis 
  Tuberculous prostatitis 
  Parasitic prostatitis 
  Mycotic prostatitis 
  Non specific granulomatous prostatitis 
 
 
  
BENIGN PROSTATIC HYPERPLASIA (BPH) 
 Benign prostatic hyperplasia represents nodular expansion of either 
prostatic glandular elements or stromal elements or both. Although 
Morgagni referred to BPH in the early 18
th
 century, it was not until the 
turn of this century that detailed anatomic observation on the ducts and 
glands were published. 
Histologic evidence of BPH can be seen in approximately 20% of 
men over 40 years of age, a figure that increases to 70% by age 60 and to 
90% by age 80.
77
 
Predisposing factors: 
No predisposing factors (other than castration & intact androgen 
supply) have been identified. As Badenoch put it, nodular hyperplasia of 
the prostate occurs “in saints and sinners, in fat men and thin, in persons 
with large families and monks with none, in postmen and prime 
ministers”4. 
 Gross features: 
The weight ranges from 40-400gm. On cross-section, the nodules 
vary in colour and consistency. In nodules that contain mostly glands, the 
tissue is yellow-pink in colour and soft in consistency. In nodules 
  
composed primarily of fibromuscular stroma, the tissue is pale gray in 
colour and firm in consistency. 
Histology: 
The hallmark of BPH is nodularity.
77
 
Frank’s classification of hyperplastic nodules29 
  The stromal (fibrous or fibrovascular) nodule 
  The fibromuscular nodule 
  The muscular nodule 
  The fibroadenomatous nodule 
  The fibromyoadenomatous nodule 
The hyperplastic glands are dilated or even cystic and may contain 
corpora amylacea. The lining epithelium is flat to columnar, the cytoplasm 
is pale and the nuclei are regular and centrally located. The nucleoli are 
inconspicuous. A continuous basal cell layer is seen above the well-
developed basement membrane.  
Special forms of benign prostatic hyperplasia 
 Clear cell and/ or cribriform hyperplasia 
 Sclerosing adenosis 
 Post atrophic hyperplasia of prostate  
 
  
Basal cell hyperplasia (BCH) 
Basal cell proliferation in prostate exhibits a morphological 
continuum ranging from focal basal cell hyperplasia to florid adenoid 
cystic carcinoma.
24
 
Patterns of benign basal cell proliferation
26, 40 
 Typical basal cell hyperplasia 
 Atypical basal cell hyperplasia 
 Basal cell adenoma 
Malignant counterpart  
 Adenoid cystic carcinoma 
In basal cell hyperplasia two or more cell layer thickness is seen at the 
periphery of the acini. The cells in basal cell hyperplasia are enlarged, 
round with large pale ovoid nuclei, finely reticular chromatin and 
moderate amount of cytoplasm.
24
 
Metaplasia in prostate 
 Transitional cell (urothelial) metaplasia 
 Mucous gland metaplasia27 
 Squamous metaplasia 
 
 
  
Association of BPH with prostate cancer 
 Cancer is found incidentally in 8- 10% of TURP specimens
92
 but 
BPH is not a premalignant lesion or a precursor of cancer.
9 
 
II. NEOPLASTIC LESIONS 
 PREMALIGNANT CONDITIONS 
Foci with the appearance of incipient carcinoma of the prostate in young 
adults may represent a type of cancer with an extraordinary long latent 
period.
91
 The two proposed histological premalignant lesions of prostate 
are 
 Prostatic intra epithelial neoplasia (PIN) 
 Atypical adenomatous hyperplasia (AAH) or adenosis 
PROSTATIC INTRA EPITHELIAL NEOPLASIA (PIN) 
Definition 
Prostatic intraepithelial neoplasia (PIN) is best characterized as a 
neoplastic transformation of the lining epithelium of prostatic ducts and 
acini. By definition, this process is confined within the epithelium 
therefore, intraepithelial.  
The term PIN was introduced in 1987 by Bostwick and endorsed by 
consensus at a 1989 international conference to replace other applications 
used in the literature for the same lesion. This consensus group also 
  
proposed that PIN to be divided into two grades (low grade and high 
grade) to replace the previous three grade system (PIN 1 – 3). 
 
TABLE 1 
PROSTATIC INTRA EPITHELIAL NEOPLASIA (PIN) 
DIAGNOSTIC CRITERIA
14 
Feature Low grade PIN High grade PIN 
Architecture  Epithelial cell 
crowding and 
stratification, with 
irregular spacing. 
More crowding and 
stratification; four patterns; 
tufting, micro papillary, 
cribriform and flat.  
Cytology  
Nuclei  Enlarged with marked 
size variation 
Enlarged; some size and shape 
variation. 
Chromatin  Normal  Increased density and clumping. 
Nucleoli  Rarely prominent. Large and prominent. Similar to 
invasive carcinoma. 
Basal cell layer Intact  May show some disruption. 
Basement 
membrane 
Intact  Intact  
 
High Grade PIN (HGPIN) 
High grade PIN has high predictive value as a marker for 
adenocarcinoma. 
 
 
  
Architectural patterns of high grade PIN are 
 Tufting  
 Micropapillary  
 Cribriform  
 Flat  
Morphological relationship of HGPIN to prostate carcinoma  
The associations of HGPIN and prostate cancer are several: 
 The incidence and extent of both lesions increase with the age 
of the patient.
80
 
 There is an increased frequency, severity and extent of HGPIN 
in prostate with cancer.
74, 79
 
 Both HGPIN and cancer are multifocal with a predominant 
peripheral zone distribution.
79
 
 Histological transition from HGPIN to cancer has been 
described. 
 High-grade PIN shares molecular genetics features with 
cancer. 
 HGPIN is more strongly associated with intermediate-high 
grade prostatic carcinoma.  
 
  
Histologic variants of high grade PIN 
 Signet-ring variant 
 Mucinous variant  
 Foamy variant  
 Inverted variant   
 Small cell neuroendocrine variant  
ATYPICAL ADENOMATOUS HYPERPLASIA (AAH) OR ADENOSIS: 
Although McNeal referred to this lesion as possible premalignant 
proliferation, to date a convincing argument for it being a precursor lesion 
has not been made by most studies.
 13, 15, 16, 30
 AAH is most often found in 
the central periurethral zone of prostate. It consists of nodular, well 
circumscribed proliferation of closely packed acini. The individual cells in 
the acini are cytologically benign. A distinctive feature is the presence of 
larger infolding glands admixed with smaller glands.  
  CARCINOMA OF PROSTATE 
The first clear description of carcinoma prostate was presented by 
Sir Henry Thompson in 1854.
62
 Mc Neal
54
 reported that carcinoma 
typically arises in the peripheral zone, although any zone can be the site of 
origin. 
  
 Malignant lesions of prostate may be of primary or metastatic in 
origin. Among the primary prostatic neoplasms epithelial tumours are 
common. Prostatic acinar adenocarcinoma is the most common type of 
epithelial tumours. When the terms "prostate cancer" or "prostate 
adenocarcinoma" are used without qualifications it refers to the common 
or acinar variant of prostate cancer. Other epithelial tumours are ductal 
adenocarcinoma, urothelial tumours, squamous and basal cell tumours. A 
variety of rare benign and malignant mesenchymal tumours arise in the 
prostate. Leiomyosarcoma of prostate is the most common type of 
sarcomas in prostate gland among adult patients. 
WHO HISTOLOGICAL CLASSIFICATION OF PROSTATIC 
TUMORS
92: 
Epithelial tumors: 
Glandular neoplasms 
 Adenocarcinoma (acinar)  
 Atrophic 
 Pseudohyperplastic 
 Foamy 
 Colloid  
 Signet ring  
  
 Carcinoma with spindle cell differentiation 
 Carcinosarcoma (Sarcomatoid carcinoma) 
 Prostatic intraepithelial neoplasia (PIN) 
 Prostatic intraepithelial neoplasia, grade III (PIN III)  
 Ductal adenocarcinoma 
 Urothelial carcinoma  
 Squamous tumors 
 Adenosquamous carcinoma  
 Squamous cell carcinoma  
 Basal cell tumors 
 Basal cell adenoma  
 Basal cell carcinoma  
 Neuroendocrine tumors 
 Prostatic stromal tumors 
 Stromal tumor of uncertain malignant potential  
 Stromal sarcoma  
 Mesenchymal tumors 
 Hematolymphoid tumors 
 Germ cell tumors 
 Metastatic tumors 
 
  
PROSTATIC ADENOCARCINOMA 
Epidemiology  
 Prostate cancer is now the sixth most common cancer in the world. 
The incidence of clinically detected adenocarcinoma varies highly among 
nations worldwide. Prostatic cancer is uncommon in Asians and occurs 
most frequently among blacks. When compared to other Asian countries, 
prostatic carcinoma is more common in India.
46
 In India, it is the fifth 
cause of cancer and fourth cause of cancer mortality in men. At some time 
in their lives approximately 1 in 22 Indian males will be stuck by prostatic 
carcinoma and its incidence is increasing by 3.5 % every year.
23
 
Age distribution 
     Worldwide, about three-quarters of cases occur in men aged 65 or 
more.    
Localization 
Most clinically palpable prostate cancers diagnosed on needle biopsy 
are predominantly located posteriorly and posterolaterally.
21, 53 
 
 
 
 
  
Clinical features: 
Signs and symptoms: 
Most of the prostate cancers are asymptomatic and detected only by 
digital rectal examination. Rarely, urinary obstruction results from large 
volume periurethral tumour. Metastatic prostatic adenocarcinoma can 
present as bone pain, mainly in the pelvic bones and spine. 
Aetiology:  
 Little is known about the aetiology of prostatic cancer. Main factors 
implicated in the aetiology are  
1. Endocrine system  
2. Genetic factors 
3. Environmental influences 
4. Dietary and hereditary factors 
Endocrine system: 
 Androgens play an important role in the development of prostatic 
cancer.  
Genetic factors: 
  Risk associated loci at 8q24 increases risk among African American 
men. Fusion of the androgen related gene TMPRSS2 (Transmembrane 
protease serine 2) and the ETS (E-twenty six) transcription factor family 
  
members particularly ERG (Ets Related Gene) is common and significant 
genomic alteration seen in prostatic cancer.
77 
Environmental factors: 
 Environmental factors as occupational exposure or behavioural 
factors do not seem to play a clear role.  
Dietary and hereditary factors: 
Increased consumption of fat, lycopenes (found in tomatoes), 
selenium, soy products and vitamin D have been implicated as the risk 
factor for prostate cancer, but none has been proven to be causative.
77
 
Macroscopy: 
On section, grossly evident cancers are firm, solid and range in 
colour from white-grey to yellow-orange. 
Histopathology: 
Architectural features 
Infiltrative small atypical glands situated in between the larger 
benign glands. 
Nuclear features 
Nuclear enlargement with prominent nucleoli is a frequent finding. 
 
 
  
Cytoplasmic features 
Glands of adenocarcinoma have a discrete crisp, sharp luminal 
border and amphophilic cytoplasm.  
Intraluminal features 
Prostatic crystalloids are commonly seen in low grade prostate 
cancer. Corpora amylacea are rarely seen in prostate cancer. 
Malignant specific features 
Perineural invasion 
Collagenous micronodules 
Glomerulations   
Histological variants 
Atrophic variant 
An unusual variant of prostate cancer resembles benign atrophy 
owing to its scant cytoplasm.  
Pseudohyperplastic variant 
Pseudohyperplastic prostate cancer resembles benign prostate glands 
in that the neoplastic glands are large with branching and papillary 
infolding.  
 
 
  
Foamy gland variant 
Foamy gland variant is characterized by having abundant foamy 
appearing cytoplasm with a very low nuclear to cytoplasmic ratio.  
Colloid & signet ring variant 
Diagnosis of mucinous adenocarcinoma of the prostate gland should 
be made when at least 25% of the tumor resected contains lakes of 
extracellular mucin.  
Oncocytic variant 
Prostatic adenocarcinoma is rarely composed of large cells with 
granular eosinophilic cytoplasm.  
Lymphoepithelioma-like variant 
This undifferentiated carcinoma is characterized by a syncytial 
pattern of malignant cells associated with a heavy lymphocytic infiltrate. 
Sarcomatoid variant (carcinosarcoma) 
  Sarcomatoid carcinoma is composed of glandular component 
showing variable Gleason score. The sarcomatoid component often 
consists of a nonspecific malignant spindle-cell proliferation.  
 
 
 
 
  
OTHER TYPES OF CARCINOMAS 
DUCTAL ADENOCARCINOMA 
 Subtype of adenocarcinoma composed of large glands lined by tall 
pseudostratified columnar cells. Although ductal adenocarcinomas are not 
typically graded, they are mostly equivalent to Gleason pattern 4. 
UROTHELIAL CARCINOMA 
The frequency of primary urothelial carcinoma ranges from 0.7-
2.8% of prostatic tumours in adults.
38, 39
 The full range of histologic types 
and grades of urothelial neoplasia can be seen in primary and secondary 
urothelial neoplasms of the prostate. 
 SQUAMOUS NEOPLASMS 
By definition pure squamous cell carcinoma does not contain 
glandular features and it is identical to squamous cell carcinoma of other 
origin. With rare exception, it does not express prostate specific antigen 
(PSA) or prostatic acid phosphatise (PAP). 
65, 88
 
BASAL CELL CARCINOMA 
 This is a neoplasm composed of prostatic basal cells. It is believed 
that a subset of basal cell is prostatic epithelial stem cells, which can give 
rise to a spectrum of proliferative lesions ranging from basal cell 
hyperplasia to basal cell carcinoma. 
 
  
NEUROENDOCRINE TUMOURS
92 
 Neuroendocrine differentiation in prostatic carcinoma has three 
forms: 
1.  Focal neuroendocrine differentiation in conventional prostatic   
adenocarcinoma 
2.  Carcinoid tumour  
3.  Small cell neuroendocrine carcinoma 
LEIOMYOSARCOMA 
Leiomyosarcomas are the most common sarcomas involving the 
prostate in adults.
22
Histologically Leiomyosarcoma range from smooth 
muscle tumors showing moderate atypia to highly pleomorphic sarcomas. 
HAEMATOLYMPHOID TUMOURS 
 Prostate is a rare site of extranodal lymphoma.
92
 
SECONDARY TUMOURS INVOLVING THE PROSTATE 
 Metastases from lung, skin (melanoma), gastrointestinal tract, 
kidney, testis and endocrine glands have been reported.
92
 
GLEASON GRADING SYSTEM (Figure 4) 
 Although numerous grading systems namely Mostofi –WHO, 
Schroder-Mostofi, M.D. Anderson Hospital, Gaeta, Muller et al and 
Gleason grading system have been proposed in the literature, only the 
Gleason grading system has prevailed.
24
 
  
The Gleason grading system named after Donald F. Gleason is the 
predominant grading system now and in 1993, it was recommended by 
WHO consensus conference.
63
 The Gleason grading system is based on 
glandular architecture; nuclear atypia is not evaluated.
33, 34
 The following 
figure shows histological patterns of prostatic adenocarcinoma.  
 
Figure 4: Standardized drawing for Gleason grading system. 
 
 
 
 
  
 This is the most powerful prognostic indicator of prostate 
carcinoma
36
. 
1.  Single, Separate, uniform glands loosely packed with definite 
edges. 
2.  Single, separate, uniform glands loosely packed with irregular 
edges. 
3A.  Single, Separate, uniform glands, scattered. 
3B.  Single, separate, very small glands, scattered. 
4A.  Fused glands, raggedly infiltrating. 
4B.  Same, with large pale cells (hypernephroid) 
5A. Almost solid, rounded masses, necrosis (“Comedocarcinoma”) 
5B.  Anaplastic, raggedly infiltrating. 
PROLIFERATIVE MARKERS 
SILVER STAINING NUCLEOLAR ORGANIZER REGIONS (AGNOR) 
  The nucleolar organizer regions (NORs) are chromosomal loops of 
DNA involved in ribosomal synthesis (Gall and Pardue 1969). Some of the 
nucleolar proteins associated with NORs are stained with silver methods 
(AgNOR proteins or AgNORs) (Derenzini and Ploton 1991). 
  
AgNORs can be identified as black dots in the nuclei. Their size and 
number reflect nucleolar and cell proliferative activity of tumors 
(Derenzini et al. 1990). 
Estimation of AgNORs parameters (number, size and distribution) 
has been applied in tumour pathology both for diagnostic and prognostic 
purposes. AgNOR number and distribution in the nucleus (configuration) 
were useful in the detection and prognosis of prostatic neoplasia.
60
 
IMMUNOPROFILE 
Prostatic immunohistochemical markers can be divided into 
following categories 
 Prostate lineage specific markers - Prostate specific antigen (PSA), 
Prostatic acid phosphatase (PAP), Prostate specific membrane antigen 
(PSMA), Human glandular kallikrein 2 (Hk2). 
 Basal cell markers - High molecular weight cytokeratins (34 betaE12), 
P63, Cytokeratin 5/6 (CK5/6). 
 Prostate cancer specific maker - Alpha Methyl-CoA racemase 
AMACR/p504s  
 Proliferation markers – proliferating cell nuclear antigen (PCNA), KI 67. 
 
 
  
 Prostate specific antigen (PSA) 
 Prostate specific antigen is a useful immunohistochemical marker 
relatively high specific for prostatic glandular cells. PSA is diagnostically 
helpful in distinguishing prostatic adenocarcinomas from other neoplasms 
secondarily involving the prostate and establishing prostatic origin in 
metastatic carcinomas of unknown primary.
28, 66
 
Basal cell markers 
 In 1953, Totten et al
85
 observed that basal cells were invariably 
lacking in prostatic adenocarcinoma. They also stated that basal cells were 
not always present in benign prostatic epithelium. This latter statement is 
indicative of how inconspicuous basal cells can be on H & E–stained 
material. It was not until the advent of immunohistochemical staining for 
cytokeratins that are preferentially expressed in basal cells, that the 
diagnostic utility of the Totten et al
85
 observation became fully 
appreciated. In 1985, Brawer et al
18
 clearly outlined the manner in which 
staining for high molecular weight cytokeratin could be used to distinguish 
a variety of benign and potentially preneoplastic processes from invasive 
carcinoma.   
 
 
  
p63 
 The recently cloned gene, p63, is a homologue of the tumor 
suppressor gene, p53. 
68, 82, 86, 93
 It is expressed in the basal cell component 
of the epithelium in a variety of human tissues and appears to be important 
in epithelial embryogenesis. 
72, 93
 
The advantages of p63 over High molecular weight cytokeratin in 
prostate immunohistochemistry are
92 
 1)  Stains a subset of 34βE12 negative basal cells. 
 2)  Less susceptible to the staining variability than 34βE12 
(particularly in TURP specimens with cautery artifact). 
 3)  Easier to interpret because of its strong nuclear staining intensity 
and low background. 
In a study by Weinstein MH false-negative staining for p63 was less 
compared with the case of high molecular weight cytokeratin. 
Alpha Methyl-CoA racemase (AMACR) 
AMACR mRNA was recently identified as being over expressed in 
prostatic adenocarcinoma. AMACR may be used as a confirmatory stain 
for prostatic adenocarcinoma, in conjunction with H&E morphology and a 
basal cell specific marker.
94
  
 
  
PROGNOSIS 
 The College of American Pathologist has classified prognostic 
factors into three categories.
10
 
Category І: (proven prognostic factors and useful in management) 
 Preoperative serum PSA level 
 TNM stage grouping 
 Histological grade as Gleason score 
 Surgical margin status 
Category II: (remains to be validated) 
 Tumor volume 
 Histologic type 
 DNA ploidy 
Category Ш: (not sufficiently studied) 
 Perineural invasion 
 Neuroendocrine differentiation 
 Microvessel density 
 Nuclear roundness 
 Chromatin texture 
 Other karyometric factors 
 Proliferation markers 
  
 PSA derivatives 
 Oncogenes, tumor suppressor genes and apoptosis genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MATERIAL AND METHODS 
 This present study is a prospective study undertaken in the 
department of pathology, Madurai Medical College, Madurai, during the 
period of May 2009 to July 2011. This study was conducted on 108 
prostatic specimens of which 56 specimens were from Government Rajaji 
Hospital, Madurai and 52 were from Madurai Kidney centre, 
Madurai.(Annexure-IV) 
 All the 108 specimens received were Trans Urethral Resection of 
Prostate (TURP) specimens ranging in volume from 1 to 10grams. These 
were fixed in 10% neutral buffered formalin for 12 hours. After adequate 
fixation, the specimens were submitted for processing until four cassettes 
were filled. Tissue processing was done with automated tissue processor 
and sections were made manually with microtome of thickness 2-4 
microns. Staining was done with routine haematoxylin and eosin 
(Annexure-III) and examined under light microscope. Silver staining of 
nucleolar organizer region (AgNOR) method of Smith and Crocker 
(Annexure-III) was done for all the cases taken for study excluding the 
cases of Leiomyosarcoma of prostate and contiguous spread of rectal 
adenocarcinoma to prostate. All the slides were examined under 100X oil 
immersion objective with 10X eye piece. One hundred lesional nuclei of 
  
epithelial cells were taken at random for the counting procedure. Careful 
focussing allowed the nucleolar organizer regions (NOR) to be visualised 
as black dots arranged both in clusters and clumps and as individual 
“satellites” within the cell nucleolus. The NOR dots were counted per 
nuclei and an average count was noted.  
 Immunohistochemical study with prostatic basal cell marker p63 
(Annexure– III) was done for various types of prostatic lesions. Ten such 
selected cases include Granulomatous prostatitis, Benign Prostatic 
Hyperplasia, atypical adenomatous hyperplasia, low grade PIN, high grade 
PIN, and adenocarcinoma. Expression of p63 was considered as nuclear 
positivity of the basal cells of prostatic epithelium.  
 Immunohistochemical study with desmin and actin were done for 
the case diagnosed as Leiomyosarcoma. Immunohistochemical study with 
PSA was done for the case of contiguous spread of rectal adenocarcinoma 
to prostate. 
With histopathological examination various prostatic lesions were 
categorised into non neoplastic and neoplastic lesions such as 
Granulomatous prostatitis, Benign Prostatic Hyperplasia, atypical 
adenomatous hyperplasia, low grade PIN, high grade PIN, prostatic 
adenocarcinoma, Leiomyosarcoma and adenocarcinomatous deposits. 
  
Histological grading was done for all the cases diagnosed as prostatic 
adenocarcinoma using Gleason grading system and Gleason histological 
scores were also noted. 
The histological data, results of AgNOR staining and results of 
immunohistochemical staining with basal cell marker, so obtained were 
analysed and compared with other similar studies. The recent literatures 
regarding prostatic lesions were also reviewed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
OBSERVATIONS 
This prospective study included 108 cases of varied prostatic lesions 
like benign, premalignant and malignant lesions. They were 
Granulomatous prostatits, Benign prostatic Hyperplasia, prostatic intra 
epithelial neoplasias (PIN), atypical adenomatous hyperplasia (AAH), 
primary prostatic adenocarcinoma, Leiomyosarcoma, and contiguous 
involvement of prostate by rectal adenocarcinoma.  
INCIDENCE OF VARIOUS PROSTATIC LESIONS: 
Benign prostatic hyperplasia was by far the most common type of 
lesion – 96 cases (88.89%), followed by malignant lesion – 10 cases 
(9.26%) and inflammatory lesions – 2 cases (1.85%). The incidences of 
various prostatic lesions are illustrated in Graph1.   
GRAPH 1  
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AGE INCIDENCE OF VARIOUS PROSTATIC LESIONS 
     The age incidence of various prostatic lesions are shown in Table 2. 
TABLE 2  
AGE INCIDENCE OF VARIOUS PROSTATIC LESIONS 
Serial 
no 
Age 
group 
Inflammatory 
condition 
BPH Malignant 
lesions 
Percentage 
1. 40-49 0 2 0 1.85% 
2. 50-59 0 18 2 18.52% 
3. 60-69 1 54 5 55.56% 
4. 70-79 1 20 3 22.22% 
5. 80-89 0 2 0 1.85% 
 
GRAPH 2 
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In our study all the cases were between the ages of 40 – 81 years. 
Incidence of both benign and malignant lesions was high in the age 
group of 60-69years. 
Among the 98 benign lesions, youngest case reported was 41 years 
old and oldest was 81 years. The mean age group for benign lesions was 
63.44. 
Among the 10 malignant lesions, youngest case reported was 50 
years old and oldest was 77 years. The mean age group for malignant 
lesions was 63.90. 
HISTOPATHOLOGY OF NON NEOPLASTIC AND NEOPLASTIC 
LESIONS 
INFLAMMATORY LESION 
 Two cases (1.85%) showed features of granulomatous prostatitis 
inclusive of both specific and nonspecific types. One case showed 
disrupted ducts and acini surrounded by granulomatous infiltration of 
foamy histiocytes multinucleated giant cells and lymphocytes which was 
suggestive of nonspecific Granulomatous prostatitis (Figure 5,6,7).Other 
case showed well formed epithelioid cell granulomas with Langhans type 
of giant cells suggestive of tuberculous Granulomatous prostatitis (Figure 
8,9). 
  
BENIGN PROSTATIC HYPERPLASIA 
Out of all the prostatic lesions studied, Nodular hyperplasia 
constituted the bulk of the lesions [88.89 %( 96cases)]. 
Light microscopic findings in benign prostatic hyperplasia 
 The light microscopic examination showed hyperplasia of both the 
glandular and stromal components (Figure 10). The glandular component 
showed variably sized glands with cystic dilatation of some them. The 
glandular lining epithelium exhibited papillary buds and infoldings which 
were prominent than the normal prostatic glands. The glands were lined by 
inner columnar cells with pale cytoplasm and uniform nuclei and outer 
intact basal cell layer. The stroma was fibromuscular. 
Associated microscopic findings in BPH 
 Benign prostatic hyperplasia showed other associated microscopic 
findings such as Lymphocytic infiltration, Corpora amylacea, Basal cell 
hyperplasia and squamous metaplasia. Incidences of associated 
microscopic findings in BPH are shown in Table 3. 
 
 
 
  
TABLE 3 
  ASSOCIATED MICROSCOPIC FINDINGS IN BPH 
Serial 
no 
Findings No of cases Percentage 
1. Lymphocytic infiltration  64 66.67% 
2. Corpora amylacea   32 29.63% 
3. Basal cell hyperplasia 10 9.26% 
4. Squamous metaplasia 2 1.85% 
 
 Among the 96 cases of BPH, 64 (66.67%) cases showed minimal 
non characteristic lymphocytic infiltration (Figure 11). The term BPH 
prostatitis is used only when there is significant inflammatory cell 
infiltrate with gland destruction.
24
 
In 32 cases of BPH, glands contained inspissated secretions of 
glycoprotein called corpora amylacea with areas of calcifications in some 
of them (Figure 12). Corpora amylacea are common in benign glands and 
only rarely seen in prostate cancer.
76
 
Foci of basal cell hyperplasia were observed in 10 cases of BPH. 
Out of which two cases showed symmetric circumferential proliferation of 
basal cells (Figure 13, 14). Sometimes basal cell proliferation may be 
mistaken for high grade PIN or carcinoma due to the presence of 
  
cytological abnormalities. These cases are of diagnostic confusion, 
particularly in needle biopsy specimens.
24
 
Squamous metaplasia is a common response to injury from various 
causes like TURP, antiandrogen hormonal therapy, infarction and 
inflammation.
24
 In our study 2 cases of BPH showed squamous metaplasia 
(Figure 15).  
Prostatic intra epithelial neoplasia (PIN) 
  Foci of low grade PIN (LGPIN) and high grade PIN (HGPIN) were 
observed in benign prostatic hyperplasia. High grade PIN was also 
associated with prostatic adenocarcinoma. Incidence of Prostatic intra 
epithelial neoplasia is shown in Table 4. 
TABLE – 4 
PROSTATIC INTRA EPITHELIAL NEOPLASIA 
Serial 
no 
  Lesions No of cases Percentage 
1. LGPIN with BPH 12 11.11% 
2. HGPIN with BPH 1 0.93% 
3. HGPIN with adenocarcinoma 2 1.85% 
 
Foci of low grade PIN were identified in12 cases of BPH which 
showed epithelial cell crowding and stratification. Nuclei were enlarged. 
Basal cell layer was intact (Figure 16). 
  
Foci of High grade PIN was identified in one case of BPH and two 
cases of prostatic adenocarcinoma which showed epithelial cell crowding 
and stratification with tufting and flat pattern. Nuclei were enlarged with 
prominent nucleoli (Figure 17). 
Atypical adenomatous hyperplasia 
In one case of BPH focal area showed atypical adenomatous 
hyperplasia in the form of nodular collection of densely packed, small, 
pale acini which merged with large complex glands (Figure 18). 
MALIGNANT LESIONS OF THE PROSTATE 
Incidence: 
In our prospective study, malignant lesions constituted the second 
most common pathology of prostate. This study included a total of 10 
cases of malignant lesions of prostate. Incidence of various malignant 
lesions observed in the study is shown in Table 5. 
TABLE 5 
MALIGNANT LESIONS OF THE PROSTATE 
Serial 
no 
Type of malignant lesion No of 
cases 
Percentage 
1. Prostatic adenocarcinoma 8 7.41% 
2. Leiomyosarcoma   1 0.93% 
3. Local invasion from Rectal 
adenocarcinoma to prostate 
1 0.93% 
  
Adenocarcinoma was the most common [7.41% (8 cases)] type of 
primary carcinoma encountered. Others were Leiomyosarcoma of prostate 
invading the bladder [1 case (0.93%)] and the Rectal adenocarcinoma 
invading the prostate [ 1 case (0.93%)].  
PROSTATIC ADENOCARCINOMA 
  Among the malignant lesions, prostatic adenocarcinoma 
account for 80%of cases. Majority of the cases were found in seventh 
decade. Age wise distribution of prostatic adenocarcinoma is shown in 
Table 6. 
TABLE 6 
AGE WISE DISTRIBUTION OF PROSTATIC 
ADENOCARCINOMA 
Serial no Age Prostatic 
adenocarcinoma 
1. 50-59 1 
2. 60-69 4 
3. 70-79 3 
 
 
 
 
 
  
GRAPH 3 
AGE WISE DISTRIBUTION OF PROSTATIC 
ADENOCARCINOMA 
 
Light microscopic findings in prostatic adenocarcinoma 
Architectural disturbances: 
 Closely packed small glands, fused glands, small atypical glands 
situated in between larger benign glands were identified along with 
diffusely arranged tumour cells. The glands were lined by single layer of 
epithelium (Figure 19, 20, 21). 
Nuclear features 
 Variable degree of differences in the size and shape of the nuclei 
was observed. Majority of the nuclei were large, hyperchromatic and 
showed prominent nucleoli (Figure 22). 
Stromal invasion: 
 Stromal invasion was found in all the cases of adenocarcinoma. 
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GRADING OF ADENOCARCINOMA OF THE PROSTATE: 
All the cases of primary prostatic carcinoma were graded using 
Gleason scoring system. Primary grade was assigned to dominant pattern 
and secondary grade to second dominant pattern and then the two numeric 
scores were added to obtain combined Gleason score. In tumours with one 
pattern of arrangement, the number was doubled.  
TABLE 7 
GLEASON GRADING SYSTEM FOR CARCINOMA 
S.NO PATH 
NO 
HPE DIAGNOSIS GLEASON 
GRADE 
GLEASON 
SCORE 
1 3667/09 Adenocarcinoma 3+3 6 
2 3909/09 Adenocarcinoma 2+2 4 
3 2674/10 Adenocarcinoma 3+4 7 
4 36/09 Adenocarcinoma 1+2 3 
5 50/09 Adenocarcinoma 1+4 5 
6 78/10 Adenocarcinoma 3+2 5 
7 25/11 Adenocarcinoma 2+3 5 
8 46/11 Adenocarcinoma 3+4 7 
 
 
 
  
TABLE 8 
INCIDENCE OF CARCINOMA WITH REFERENCE TO 
GLEASON SCORE 
Serial no GLEASON SCORE NO OF 
CASES 
PERCENTAGE 
1. 3-4 2 25% 
2. 5-7 6 75% 
 
GRAPH – 4 
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Gleason score of 5-7 was the commonest, seen in 6 cases. Gleason 
score of 3-4 was seen in 2 cases.  
Perineural invasion: 
Only one case showed the evidence of perineural invasion in the 
present study (Figure 23, 24). 
MICROSCOPIC FINDINGS IN LEIOMYOSARCOMA: 
One case of Leiomyosarcoma was noted in the present study. The 
tumour was composed of interlacing fascicles of spindle cells with blunt 
ended nuclei and eosinophilic cytoplasm with nuclear atypia and increased 
mitotic activity. (Figure 25, 26, 27) This tumour was positive for 
immunohistochemical staining with desmin (Figure 28) and actin. 
MICROSCOPIC FINDINGS IN CONTIGUOUS SPREAD FROM 
RECTAL ADENOCARCINOMA 
 In one case contiguous involvement of prostate by rectal 
adenocarcinoma was seen which was found to be negative for 
immunostaining with PSA. The prostate was removed in piecemeal along 
with Abdomino Perineal Resection done for rectal adenocarcinoma 
(Figure 29). 
 
 
  
SERUM PSA LEVEL 
 Total serum PSA levels were done in only 33 cases of which 30 
cases were benign and 3 cases were malignant. Serum PSA level more 
than 10ng/ml was seen in 2 benign cases and 3 malignant cases. Serum  
PSA level of benign and malignant cases is shown in Table 9.  
TABLE – 9 
SERUM PSA LEVEL 
Serum PSA 
level 
Benign lesions Malignant 
lesions 
Total 
0-4.0ng/ml 20 (60.61%) - 20 (60.61%) 
4.1-10.0ng/ml 8 (24.24%) - 8 (24.24%) 
10.1-20.0ng/ml 2 (6.06%) 2 (6.06%) 4 (12.12%) 
>20ng/ml - 1(3.03%) 1(3.03%) 
 
GRAPH – 5 
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PROLIFERATIVE MARKER STUDY 
Results of silver staining nucleolar organizer regions (AGNOR): 
Mean AgNOR count: 
 Mean AgNOR count was higher in malignant lesions when 
compared to benign lesions. (Figure 30, 31, 32) 
TABLE - 10 
THE MEAN AgNOR COUNT IN VARIOUS PROSTATIC LESIONS 
Serial 
no 
Lesions No of 
cases 
Mean AgNOR 
count 
1. Granulomatous prostatitis 2 1.9 
2. BPH with or without prostatitis 83 1.43 
3. BPH with LGPIN  11 2.08 
4. BPH with AAH 1 2.3 
5. BPH with HGPIN 1 3.9 
6. Adenocarcinoma 8 4.81 
 
Note:  LGPIN and AAH were noted in the same case.  (1091/10) and 
included as BPH with AAH in the above table. 
 
 
 
  
TABLE 11 
MEAN AgNOR COUNT IN BENIGN AND MALIGNANT LESIONS 
 Range Mean AgNOR count 
Benign 1.2-1.7 1.44 
PIN 1.9-3.9 2.23 
Malignant 4-5.2 4.81 
 
GRAPH – 6 
MEAN AgNOR COUNT IN VARIOUS PROSTATIC LEIONS 
 
 
 
 
 
 
 
 
One way Analysis Of Variance test was used to assess the statistical 
difference between benign, premalignant and malignant lesions. 
The differences in the mean value between benign and pre malignant 
lesions were statistically significant. (P = < 0.001). 
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The differences in the mean value between benign and malignant 
lesions were statistically significant. (P = < 0.001). 
PROSTATIC BASAL CELL MARKER STUDY 
Results of immunohistochemical staining with P63 
  The following cases were selected for immunohistochemical 
staining with prostatic basal cell marker p63. 
TABLE 12 
SERIAL  
NO 
PATH NO HPE DIAGNOSIS 
1 21/10 Granulomatous prostatitis 
      2         83/10 BPH 
3 1091/10 BPH with AAH & LGPIN 
4 4027/09 BPH with LGPIN 
5 119/11 BPH with LGPIN 
6 37/09 BPH with LGPIN 
7 103/10 BPH with HGPIN 
8 50/09 Adenocarcinoma with HGPIN 
9 36/09 Adenocarcinoma with HGPIN 
10 2674/10 Adenocarcinoma (3+4) 
 
Continuous staining of basal cells was observed in benign glands, 
foci of low grade PIN and atypical adenoamatous hyperplasia. (Figure 33, 
34) Focal discontinuity in basal cell staining was observed in high grade 
  
PIN areas. (Figure 35) Complete absence of basal cell staining was seen in 
adenocarcinoma. (Figure 36, 37)  Interestingly discontinuous basal cell 
staining was seen in disrupted glands of Granulomatous prostatitis. (Figure 
38) 
TABLE 13 
COMPARISON BETWEEN MEAN AGNOR COUNT AND 
IMMUNOREACTIVITY FOR P63 
Type of lesion Mean AgNOR count Staining pattern with p63 
Benign  1.44 Continuous 
Low grade PIN 2.08 Continuous 
AAH 2.3 Continuous 
High grade PIN 3.9 Focal discontinuity 
Malignant 4.81 Absent 
     
 
 
 
 
 
 
  
GRAPH 7 
COMPARISON BETWEEN MEAN AGNOR COUNT AND 
IMMUNOREACTIVITY FOR P63 
 
  
In this study the AgNOR count which is the marker for proliferative 
index showed an increase in malignant lesions when compared to that of 
benign lesions. The normal prostatic basal cell marker is p63. On 
immunohistochemical staining with p63, basal cells were completely 
absent in malignant lesions and they were present in benign lesion.  
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Figure 5: Nonspecific granulomatous prostatitis showing 
granulomas with destruction of acini. (H & E 100X) (21/10)
Figure 6: Nonspecific granulomatous prostatitis showing 
disrupted acini surrounded by granulomatous infiltration of 
foamy histiocytes. (H & E 400X) (21/10) 
  
       
Figure 7: Nonspecific granulomatous prostatitis showing 
foamy histiocytes and multinucleated giant cells. (H & E 400X) 
(21/10) 
 
Figure 8: Tuberculous Granulomatous prostatitis showing 
epithelioid cell granulomas with Langhans type of giant cells. 
(H & E 100X) (20/11) 
  
 
 
Figure 9: Tuberculous Granulomatous prostatitis showing 
Langhans type of giant cell. (H & E 400X) (20/11) 
 
 
Figure 10: Benign prostatic hyperplasia showing nodules of 
hyperplastic glands. (H & E 100X) (119/11) 
  
 
 
Figure 11: Non characteristic lymphocytic infiltration in benign 
prostatic hyperplasia. (H & E 100X) (3226/09) 
 
 
Figure 12: Corpora amylacea within the glandular lumina in 
benign prostatic hyperplasia. (H & E 100X) (119/11) 
 
  
 
 
Figure 13:  Benign prostatic hyperplasia showing 
circumferential proliferation of basal cells. (H&E 100X) 
(3678/09) 
 
 
Figure 14: Basal cell hyperplasia highlighted with basal cell 
immunostain p63. (100X) (50/09) 
  
 
 
Figure 15: Squamous metaplasia in benign prostatic 
hyperplasia. (H&E 100X) (4027/09) 
 
 
 
Figure 16: Low grade PIN foci showing epithelial cell 
crowding and stratification.  (H&E 100X) (4027/09) 
  
 
Figure 17: Foci of High grade PIN showing epithelial cell 
crowding and stratification in tufting pattern with enlarged 
nuclei and prominent nucleoli. (H&E 400X) 
 
Figure 18: Benign prostatic hyperplasia showing foci of 
atypical adenomatous hyperplasia. (H&E 100X) (1091/10) 
 
  
 
Figure 19: Prostatic adenocarcinoma Gleason pattern 2 –
loosely packed single glands with irregular edges. (H&E 
100X) (78/10) 
 
Figure 20: Prostatic adenocarcinoma Gleason pattern 3 – 
scattered single glands. (H&E 100X) (78/10) 
  
  
Figure 21: Prostatic adenocarcinoma Gleason pattern 4 – 
fused infiltrating glandular pattern. (H&E 100X) (2674/10) 
 
Figure 22: Prostatic adenocarcinoma cells showing 
prominent nucleoli and mitosis. (H&E 400X) (2674/10) 
  
  
Figure 23: Prostatic adenocarcinoma showing perineural 
invasion. (H&E 400X) (3667/10) 
  
Figure 24: Prostatic adenocarcinoma showing perineural 
invasion. (H&E 400X) (3667/10) 
  
  
Figure 25: Prostatic parenchyma with Leiomyosarcoma. 
(H&E 100X) (81/10) 
  
Figure 26: Leiomyosarcoma showing interlacing fascicles of 
tumour cells. (H&E 100X) (81/10) 
  
  
Figure 27: Leiomyosarcoma showing spindle cells with blunt 
ended nuclei and eosinophilic cytoplasm with nuclear atypia. 
(H&E 400X) (81/10) 
  
Figure 28: Leiomyosarcoma showing positivity for desmin 
with immunohistochemistry.  (400X) (81/10) 
  
  
Figure 29: Rectal adenocarcinoma deposits in prostate. 
(H&E 100X) 
Inset: Tumour deposits showing negativity for PSA 
with immunohistochemical study. (100X) (2598/09) 
  
Figure 30: BPH showing occasional AgNOR dots per nuclei. 
(AgNOR stain 1000X) (2116/10) 
  
  
Figure 31: High grade PIN showing two to three AgNOR dots 
per nuclei. (AgNOR stain 1000X) (103/10) 
  
Figure 32: Prostatic adenocarcinoma showing numerous 
AgNOR dots per nuclei. (AgNOR stain 1000X) (2674/10) 
  
  
Figure 33: Foci of low grade PIN showing continuous basal 
cell immunostaining with p63. (100X) (4027/09) 
  
Figure 34: Foci of Atypical Adenomatous Hyperplasia 
showing continuous basal cell immunostaining with p63. 
(100X) (1091/10) 
 
  
  
Figure 35: Foci of high grade PIN showing discontinuous 
basal cell immunostaining with p63. (400X) (103/10) 
  
Figure 36: Prostatic adenocarcinoma showing absent basal 
cell immunostaining with p63. (100X) (2674/10) 
  
  
Figure 37: Grade 3 prostatic adenocarcinoma showing 
infiltrating malignant glands between benign glands with p63 
immunostaining. (100X) (2674/10) 
  
Figure 38: Granulomatous prostatitis showing discontinuous 
basal cell immunostaining with p63 in centre of granuloma. 
(100X) (21/10) 
  
 
  DISCUSSION 
Prostate hosts a number of diseases ranging from inflammation to 
carcinoma. This leads to a considerable morbidity and mortality 
worldwide.  
This current study aims at the analysis of histopathological features 
of various non neoplastic and neoplastic lesions of the prostate including 
the grading of malignant lesions and evaluation of role of basal cell and 
proliferative markers in different benign, premalignant and malignant 
lesions of prostate.  
INFLAMMATORY LESIONS 
GRANULOMATOUS PROSTATITS 
 Granulomatous prostatitis is noticed occasionally in TURP 
specimens. Clinically, it presents as a focal or diffuse area of induration 
and is often mistaken for carcinoma. Incidence of granulomatous 
prostatitis was 1.4% in a study by H Mohan et al 
61 
which is similar to our 
study (1.85%). 
 BENIGN PROSTATIC HYPERPLASIA (BPH) 
The incidence of BPH increases with age. BPH is seen in 20% of the 
men at 40 years of age, a figure that increases to 70% by age of 60 and to 
90% by age of 80.
77
  
  
In the present study 108 cases of TURP specimen were examined. 
Benign prostatic hyperplasia was seen in 96 cases. Highest incidence of 
nodular hyperplasia was noted in the 7th decade. The number of cases in 
various age groups is shown in the graph 8 
GRAPH 8 
AGE DISTRIBUTION OF BPH 
 
 
 
 
 
 
 
 
In a classic paper by Berry et al, the prevalence of BPH ranged from 
8% for men in their 30s to 88% for men over 80s.
7
 In another classic paper 
Issac and Coffey compared the prevalence of BPH by age in autopsy 
studies from various countries. This study demonstrated relatively similar 
prevalence of BPH across a spectrum of countries and ethnicities.
41
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In our study also the incidence of BPH increases with age reaching 
maximum in 7
th
 decade. The decline in the number of cases beyond the 
age of 80 years may reflect the average life span of people in our country. 
Associated microscopic findings in BPH 
In BPH minimal periglandular and non characteristic cellular 
infiltrates are seen in 60% to70% of cases.
24
 In this study 64 cases 
(66.67%) of BPH showed focal or diffuse lymphocytic infiltration. The 
term BPH prostatitis is used when there is significant inflammatory cell 
infiltrate with gland destruction; however this type of BPH prostatitis is 
seen in 30% of all cases.
24
  
In a study by Mittal BV et al basal cell hyperplasia was present in 
8.9% of transurethral specimens.
59
 In our study 10 cases (9.26%) of BPH 
showed basal cell hyperplasia which is comparable with the above study. 
Squamous metaplasia is a common response to injury from various 
causes like TURP, antiandrogen hormonal therapy, infarction and 
inflammation
24
. In our study two cases of BPH showed squamous 
metaplasia.  
 
 
 
  
Prostatic Intra Epithelial Neoplasia (PIN) 
PIN has high predictive value as a marker for adenocarcinoma. This 
is particularly true for high grade PIN; if this lesion is identified; close 
surveillance and follow up biopsy are indicated.
24
 Incidence of cancer after 
follow up of high grade PIN is shown in Table 14.  
     TABLE: 14 
Serial 
no 
Investigator Cases of 
HGPIN (N) 
Cancer on 
follow up (%) 
1. Brawer et al
19
  21 12 
2. Weinstein et al
90
  19 10 
3. Davidson et al
25
 100 33 
4. Markham et al
50
 32 13 
5. Berner et al
6
 37 14 
 
The frequency of HGPIN in transurethral resection of the prostate 
specimens is between 2.3% and 4.2 %.
8, 32, 57
 The present study was 
comparable well with the above study, stating 2.78% prevalence of 
HGPIN in all TURP specimens. 
The frequency of HGPIN in prostates involved with cancer is 
significantly increased when compared with the cancer free prostates.
24
The 
  
frequency of high grade PIN in prostates with and without cancer is shown 
in Table 15. 
TABLE: 15 
Serial 
no 
Authors Specimen 
source 
HGPIN 
with 
carcinoma 
HGPIN 
without 
carcinoma 
1. Mc Neal and 
Bostwick
55
 1986 
Autopsy 82% 43% 
2. Wael A. Sakr
 
and 
Alan W. Parti
89
(2001) 
Autopsy 63% -93% 25% - 43% 
3. Present study TURP 25% 1% 
 
The incidence of high grade PIN is low in our study because all the 
specimens were TURP which does not have enough material compared to 
whole prostate specimen examined in other studies. In a study by Pacelli A 
and Bostwick DG the incidence of high grade PIN in TURP specimens 
without carcinoma was 2.8%.
69
The incidence of PIN in prostatic 
malignancy, as quoted in the literature, varies from 33% to 100%, 
depending on the nature of specimen.
12, 45, 56, 75, 87
 In our study, we observed 
high grade PIN in 25% of the carcinomas. 
  
Low grade PIN foci were identified in 12 cases of BPH. 
Interobserver agreement on HGPIN is “good to excellent,” whereas that 
for Low grade PIN may be too great to justify its diagnostic use. Despite 
this concern LGPIN is been reported, recognizing that this for research 
purpose.
24
 
Atypical Adenomatous Hyperplasia (AAH) 
Gaudin and Epstein estimated the incidence of AAH as 1.6% in 
TURP specimens.
11, 30, 31
 In the present study the incidence of Atypical 
Adenomatous Hyperplasia (0.93%) is slightly lower than the above study. 
MALIGNANT LESIONS OF PROSTATE 
In this study, malignant lesions account for 9.26% (10 cases) of 
cases. Among the malignant lesions incidence of primary prostatic 
adenocarcinoma is high [8cases (80%)]. 
PROSTATIC ADENOCARCINOMA 
Prostate cancer is now the sixth most common cancer in the world.
71
 
The prevalence of prostatic adenocarcinoma in this study is 7.41% (8 
cases). All these cases were incidental adenocarcinoma which were 
identified in transurethral resection of the prostate (TURP) done for BPH.  
According to WHO study, when TURP is done without clinical suspicion 
  
of cancer, prostate cancer is incidentally detected in approximately 8- 10% 
of the specimens
92
, which is in correlation with our study. 
 The risk of prostate cancer rises very steeply with age. Worldwide, 
about three-quarters of all cases occur in men aged 65 or more.
92
In our 
study also maximum numbers of cases were found in the age group of 60-
69 years. 
GLEASON GRADING SYSTEM: 
Gleason scoring system is the most widely used and officially 
recommended system for scoring prostatic adenocarcinoma.
2, 35
 Gleason 
score correlates with prognosis after radical prostatectomy and with 
outcome following radiotherapy. Gleason grade on biopsy can influence 
mode of treatment. 
We applied Gleason grading system for all adenocarcinoma. 
(Table7) 
The original Gleason grading system does not account for tertiary 
patterns occupying less than 5% of the tumour. When this tertiary pattern 
accounted is pattern 4 or 5, it should be reported in addition to the Gleason 
score, even if it is less than 5% of the tumour since it is associated with 
adverse prognosis.
70
 
 Tertiary high grade Gleason patterns were observed in two cases. 
  
TABLE 16 
Serial no PATH NO HPE DIAGNOSIS GLEASON 
GRADE 
1. 3667/09 Adenocarcinoma 3+3+4 
2. 2674/10 Adenocarcinoma 3+4+5 
 
  According to Association of Directors of Anatomic and Surgical 
Pathology (ADASP) Prostate Carcinoma Guideline (Updated September 
2006, Version 1.4) in TURP, enucleation, and radical prostatectomy 
specimens, the Gleason score is based on the primary (most common) and 
secondary (next most common) pattern. If there is a third pattern or if the 
second pattern occupies is less than 5% of the specimen, then this pattern 
is reported as a tertiary pattern.
1
  
LEIOMYOSARCOMA  
Leiomyosarcoma of prostate is the most common type of sarcomas 
in prostate gland among adult patients. This tumour, in general accounts 
for less than 0.1% of prostate malignancies.
48
 In this study one case 
(0.93%) of Leiomyosarcoma was observed which was confirmed by 
immunohistochemical study with desmin and actin.  
 
  
CONTIGUOUS SPREAD FROM RECTAL ADENOCARCINOMA 
Prostate carcinoma and colorectal carcinoma constitute 2 of the 3 
leading malignancies in males both in term of frequency of diagnoses and 
mortality.
42
Given the anatomic proximity of the 2 organs, locally advanced 
Prostate carcinoma can involve adjacent colorectal tissue.
5,17,64
 Similarly, 
advanced colorectal carcinoma can rarely invade into prostate.
49
   
 In this study one case (0.93%) of local invasion from rectal 
adenocarcinoma was noted and it was found to be negative for 
immunostaining with PSA, thus ruling out the primary prostatic 
adenocrcinoma. 
SERUM PSA (PROSTATE SPECIFIC ANTIGEN) LEVELS: 
 In the present study only 33 cases had serum PSA level estimated. 
Out of 33 cases 30 were benign. A total of 8 cases (24.24%) of BPH 
showed modest elevation of serum PSA (4.1-10.0ng/ml). Studies of 
patients with histologically confirmed BPH have shown that 21% to 86% 
have an elevated serum PSA.
67 
Conditions that disrupt barriers for PSA 
access into the vasculature result in elevation of serum PSA.
24
 Such serum 
elevation can be caused by benign conditions like BPH, prostatic 
inflammation, infarct or prostatic manipulation and malignant diseases. 
  
Two cases of Granulomatous prostatitis showed elevation of PSA more 
than 10ng/ml. 
 High levels of serum PSA is seen in prostatic cancer and it is the 
most important tumour marker for adenocarcinoma of prostate.
24
 In this 
study two case of prostatic adenocarcinoma showed serum PSA levels 
between 10.1-20.0ng/ml and one case showed PSA level >20ng/ml.  
 Serum PSA lacks high sensitivity and specificity for prostate cancer. 
This problem has been partially overcome by calculating several PSA-
related indices (PSA density, Prostate-specific antigen epithelial density. 
PSA velocity and PSA doubling time).
92
 PSA tests are also useful to detect 
recurrence and response of cancer following therapy. 
AgNOR COUNT  
 Tumor differentiation and proliferative activity are important 
predictors of biological behavior. While routine histological evaluation is 
fairly adequate to assess differentiation, tumor proliferative activity is 
difficult to measure. Silver staining for nucleolar organizer regions 
(AgNORs) is reported to be helpful for assessing tumor proliferation. 
AgNOR value is significantly higher in Prostatic carcinoma than 
BPH, AAH &PIN. It is also significantly higher in PIN than BPH. 
  
 Our study showed identical results with the study done by Asim 
Kumar Manna et al.
3
 Kawase
43
 found AgNOR counts were higher in 
carcinoma (4.2+/- 1.57) than in benign lesions (1.9 +/- 0.24). Wael A sakr 
found that AgNOR study is helpful in assessing tumour proliferation.
81
 
TABLE 17 
COMPARISON OF MEAN AGNOR COUNT IN  
VARIOUS STUDIES 
Serial no Studies  BPH PIN Prostatic 
adenocarcinoma 
1. Sakr, W. A
81 
1.836 3.129 4.737 
2. Asim Kumar Manna
3 
1.3 4.7 4.91 
3. Present study 1.44 2.23 4.81 
 
 Results of the present study are comparable with the above studies. 
IMMUNOHISTOCHEMISTRY WITH P63 
 P63 is most abundantly represented in normal prostate basal cells 
and it is a reliable prostate basal cell marker. Because basal cells with p63 
protein are consistently undetectable in prostate cancers, p63 expression 
may be used in the differential diagnosis between benign and malignant 
lesions of the prostate.
58
  
  
 This marker has the disadvantage that a diagnosis of cancer is based 
on negative staining. Benign conditions like atrophic glands (25%), basal 
cell hyperplasia (12%) and atypical adenomatous hyperplasia (10-90%) 
may show negative staining with basal cell markers. So it is critical to 
study the immunostained sections with a positive internal control. Benign 
glands with a strong positive signal were taken as controls. 
 A combination of basal cell markers and α-methylacyl-CoA 
racemase (AMACR), has increased the sensitivity for the diagnosis of  
prostate cancer rather than basal cell markers. 
47
    
 Granulomatous prostatits is a distinctive form of prostatits that can 
be misdiagnosed as carcinoma clinically,
 44, 83, 84
 radiologically
20, 78, 
and 
histopathologically.
73
 Interestingly in our study the glands in the centre of 
the granuloma showed absence of basal cells. This shows that while 
interpreting basal cell marker immunostaining, attention should be given 
to surrounding inflammation also. This is the disadvantage of using basal 
cell marker alone as a diagnostic tool.
 
 Increasing grades of PIN were associated with progressive 
disruption of basal cell layer.
8
 In this study basal cell layer disruption was 
seen in foci of high grade PIN areas. 
  
 In our study suspected areas of atypical adenomatous hyperplasia in 
benign prostatic hyperplasia showed continuous staining with p63 which 
proved that the lesion was benign. As definite diagnosis was arrived with 
p63 in this case AMACR was not done. So p63 staining is useful in 
diagnosing gray zone cases. 
 In this study malignant glands consistently failed to express 
immunoreactivity to antibody against p63, whereas normal prostatic acini 
invariably were stained for basal cells. 
 When the results of AgNOR and p63 staining were compared 
AgNOR index (the proliferative activity) and invasiveness (lack of basal 
cell layer) increases from benign to malignant end in the spectrum of 
prostatic lesions. 
 
 
 
 
 
 
 
 
  
SUMMARY 
In the present prospective study comprising 108 cases of prostatic 
lesions which were evaluated with light microscopy, AgNOR staining and 
Immunohistochemistry, following conclusions were made and presented. 
1.  BPH was the most common lesion affecting the prostate in elderly 
[96 cases (88.89%)]. 
2.  The age incidence of Nodular Hyperplasia was high in 7
th
 decade [54 
cases (56.25%)]. 
3.  Chronic non specific inflammatory cell infiltration [64 
cases(66.67%)], foci of basal cell hyperplasia [10 cases (29.63%)] 
and squamous metaplasia [2 cases(1.85%)] were seen associated 
with BPH. 
4.  Granulomatous prostatitis was rarely encountered [2 cases (1.85%)]. 
5.  HGPIN had high degree of association with prostatic carcinoma 
(25%). 
6.  Among the malignant lesions of the prostate, primary prostatic 
adenocarcinoma was the commonest (80%). 
7.   According to Gleason Grading system higher grades were more 
commonly observed as the predominant pattern. 
  
8.  Mean AgNOR counts (proliferative activity) were higher in 
malignant lesions (4.81) when compared with the benign lesions 
(1.44).  
9. With Immunohistochemical staining invasiveness increasesd from 
benign (continuous staining) to malignant (absence of staining) end 
in the spectrum of prostatic lesions. 
10. Two rare cases, Leiomyosarcoma of prostate and contiguous spread 
of rectal adenocarcinoma to prostate were observed in the present 
study which were confirmed with immunohistochemical study with 
desmin and PSA respectively. 
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
 
Interpretation of prostatic biopsies has been a continuous problem 
for practising pathologist. Various types of difficulties have been 
encountered while diagnosing and typing prostatic carcinoma and 
premalignant lesions especially in TURP specimens. Mean AgNOR counts 
are significantly higher in adenocarcinoma when compared to benign and 
premalignant lesions and correlated with histological grade of the tumour. 
Prostatic basal cell marker p63 expression may be used in the differential 
diagnosis between benign and malignant lesions of the prostate with its 
limitations.  We conclude that basal cell markers and proliferative markers 
have significant role in the diagnosis of prostatic lesions especially which 
fall in the premalignant category and which create difficulty in the 
diagnosis by routine histopathological study. 
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ANNEXURE - II 
PROFORMA 
Serial  no:       Name :                               Age:     
Path no   :          Address: 
Serum PSA: 
Provisional diagnosis: 
Nature of specimen received: Biopsy, TURP, Prostatectomy. 
Gross examination: 
Weight:    size:   colour:    shape:    consistency: 
Presence of nodules, cysts, calculi & suspicious area of carcinoma: 
Histopathological examination: 
BPH 
PIN: low grade, high grade 
Malignancy: primary, secondary 
Adenocarcinoma-Gleason grading 
Associated PIN 
Perineural/ lymphatic invasion 
Inflammatory lesion 
Proliferative marker: 
AgNOR,  
 Immunohistochemistry: 
P63 – prostatic basal cell marker  
  
ANNEXURE- Ш 
1. HAEMATOXYLIN AND EOSIN STAINING METHOD 
  
1. Sections were dewaxed with xylene for 20 minutes. 
2. Sections were hydrated through descending concentrations (absolute 
alcohol, 90%, 70%, 50%) of ethanol to water solutions. 
3. Sections were rinsed in distilled water. 
4. Sections were placed in Ehrlich haematoxylin stain for 20-30 minutes. 
5. Rinsed with water. 
6. Differentiation was done by immersing the sections in 1% acid alcohol for 
10 seconds. 
7. Rinsed with water. 
8. Blueing was done by keeping the sections in scott’s tap water for 2-10 
minutes. 
9. Counterstained with 1% aqueous eosin for 1-3 minutes. 
10. Rinsed with water. 
11. Dehydrated through increasing concentration of ethanol solutions (50%, 
70%, 95%, absolute alcohol) and cleared with xylene.  
12. Mounted with DPX 
 
 
  
2.  AgNOR STAINING OF SMITH AND CROCKER : 
1. Sections were dewaxed with xylene for 20 minutes. 
2. Sections were hydrated through descending concentrations of 
(absolute alcohol, 95%, 70%, 50%) ethanol to water solutions. 
3. Sections were rinsed in distilled deionised water. 
4. Sections were treated with freshly prepared working solution made 
up of one volume of 2gm/ml gelatine in 1% formic acid solution and 
two volumes of  50% aqueous silver nitrate solution for 45 minutes 
in dark at room temperature. 
5. Washed with distilled deionised water for 1 minute. 
6.   Dehydrated through increasing concentration of ethanol (50%, 70%, 
95%, absolute alcohol)solutions and cleared with xylene. 
7.   Mounted with DPX. 
 
 
 
 
 
 
 
  
3.   IMMUNO HISTOCHEMICAL STAINING FOR P63 
1.  3-5 microns thick sections were cut from the blocks and sections 
were received on slides coated with poly- L – lysine. 
2.  Slides were kept in hot air oven at 60
0 
C for 3 hrs. 
3.  Sections were dewaxed in two changes of xylene each for 10 
minutes. 
4.  Sections were hydrated in graded ethanol solution (95%, 70%, and 
50%) each for 3 minutes and in running tap water for 3 minutes. 
5.  Heat induced antigen retrieval was done with Retrieval buffer 
solution (Tris buffer 1.81gm + EDTA 0.55gm + Distilled water 
1500ml) in pressure cooker. 
6.  Sections were washed with distilled water for 5 minutes. 
7.  Then sections were washed with Tris buffer solution of PH 7.4-7.6 ( 
Tris 24gm + Sodium chloride 21.5gm + distilled water 2.5 litre + 
Tween 20 5µl/lr) for 5 minutes. 
8.  Sections were treated with 1-2 drops of hydrogen peroxide (H2O2 
3ml+dist water 97ml) for 5-10 minutes to block endogenous 
peroxidise enzyme activity.  
9.  Sections were washed with Tris buffer solution for 5 minutes. 
10.  Sections were treated with primary antibody p63 for 1 hour. 
  
11.  Sections were washed with Tris buffer solution for 5 minutes. 
12.  Secondary antibody polymer HRP (Horse Radish Perxidase) was 
applied for 45 minutes. 
13.  Sections were washed in two changes of Tris buffer solution each for 
5 minutes. 
14. Sections were treated with chromogen Diamino Benzidine (DAB) 
for 15 minutes. 
15. Sections were washed with Tris buffer solution for 5 minutes. 
16. Then washed in running tap water for 2 minutes. 
17. Counterstained with Haematoxylin for 1-2 minute. 
18. Mounted with coverslip. 
 
 
 
 
 
 
 
 
 
  
 
ABBREVIATIONS USED IN MASTER CHART 
 
PSA PROSTATE SPECIFIC ANTIGEN 
FMH FIBRO MUSCULAR HYPERPLASIA 
BCH BASAL CELL HYPERPLASIA 
PIN PROSTATIC INTRAEPITHELIAL NEOPLASIA 
AgNOR SILVER STAINING OF NUCLEOLAR ORGANIZER 
REGION 
IHC IMMUNO HISTOCHEMISTRY 
BPH BENIGN PROSTATIC HYPERPLASIA 
LGPIN LOW GRADE PROSTATIC INTRAEPITHELIAL 
NEOPLASIA 
AAH ATYPICAL ADENOMATOUS HYPERPLASIA 
HGPIN HIGH GRADE PROSTATIC INTRAEPITHELIAL 
NEOPLASIA 
 
 
  
        ANNEXURE - IV   MASTER CHART    
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1 Mayilsamy  54 2140/09 BPH   6cc + + + - - - - - 1.8 - BPH 
2 Solairaj  62 2141/09 BPH   4cc + + + + LGPIN - - - 1.9 - 
BPH with 
LGPIN 
3 Pitchumani  60 2471/09 BPH   1occ + + + + LGPIN - - - 2.3 - 
BPH with 
LGPIN 
4 Karupasamy  50 2598/09 
Rectal 
adeno 
carcinoma 
  4cc - - - - - 
Adeno 
carcinoma 
deposits 
- - - 
PSA - 
Negative 
Adeno 
carcinoma 
deposits 
5 Chellamuthu  58 3219/09 BPH   5cc + + + - - - - - 1.6 - BPH 
6 Arumugam 62 3222/09 BPH   5cc + + - - - - - - 1.2 - BPH 
7 Karuppasamy  60 3224/09 BPH   6cc + + + + - - - - 1.6 - BPH 
8 Madavan  62 3226/09 BPH   8cc + + + + LGPIN - - - 1.6 - 
BPH with 
LGPIN 
9 Kaja maideen 55 3667/09 BPH   8cc     _ _     + 3+3 5.1   
prostatic 
adeno 
carcinoma 
(3+3) 
10 Krishnan  58 3678/09 BPH   6cc + + + + - - - - 1.7 - BPH  
11 Vellai samy 61 3693/09 BPH   4cc + + + - LGPIN - - - 1.6 - 
BPH with 
LGPIN 
12 Aandiappan  40 3694/09 BPH   4cc + + + - - - - - 1.4 - BPH  
13 Sundar rajan 65 3909/09 BPH   6cc - - - - - - + 2+2 4.5   
Prostatic 
adeno 
carcinoma 
(2+2)score 4 
14 Muthalagu  67 3910/09 BPH   3cc + + + - - - - - 1.5 - BPH 
  
15 Shahul hameed 60 4023/09 BPH   3cc + + _ - - - - - 1.6 - BPH 
16 Raju  60 4027/09 BPH   6cc + + + + LGPIN 
squmamous 
metaplasia 
- - 2.2 
P 63 - 
Continuous  
BPH with 
LGPIN 
17 Nerinji  62 4157/09 BPH   5cc + + + + LGPIN - - - 2.1 - 
BPH with 
LGPIN 
18 Liyagath Ali 55 4158/09 BPH   3cc + + _ - - - - - 1.6 - BPH 
19 Jeya raj 50 4171/09 BPH   3cc + + _ _ - - - - 1.5 - BPH 
20 Srinivasan  55 37/10 BPH  3cc + + + _ - - - - 1.5 - BPH 
21 Aasirvatham  55 113/10 BPH   4cc + + + _ - - - - 1.5 - BPH 
22 Pethu chettiyar 67 306/10 BPH   5CC + + _ - - - - - 1.4 - BPH 
23 Edwin  66 362/10 bph   5CC + + + - - - - - 1.4 - BPH 
24 Kumarasamy  65 597/10 bph   4CC + + _ _ - - - - 1.5 - BPH 
25 Muthaiah  48 654/10 bph   2CC + + + _ - 
squmamous 
metaplasia 
- - 1.5 - BPH 
26 Mandha devar 68 754/10 BPH   1cc + + _ - - - - - 1.4 - BPH 
27 Shanmuga vel 55 824/10 BPH   2cc _ + - _ - - - - 1.4 - BPH 
28 Ramayan  60 1074/10 BPH   4cc + + + - - - - - 1.5 - BPH 
29 Raju  58 1091/10 BPH   5cc + + + - 
LGPIN, 
AAH 
- - - 2.3 
P 63 - 
Continuous  
BPH with 
LGPIN 
30 Malaiyandi  65 1498/10 BPH   5cc + + - - - - - - 1.3 - BPH 
31 Mayil samy 79 2116/10 BPH   3cc + + - - - - - - 1.3 - BPH 
32 Arunachalam  68 2117/10 BPH   4cc + + _ + - - - - 1.4 - BPH 
33 Jeyaraman  60 2437/10 BPH   4cc + + + - - - - - 1.5 - BPH 
34 Kaja maideen 70 2674/10 BPH   3cc - - - - - - + 3+4 5.5 
P 63 - 
Absent 
Prostatic 
adeno 
carcinoma 
(3+4)score 7 
35 Chokka lingam 62 2851/10 BPH   4cc + + - - - - - - 2.1 
P 63 - Focal 
dis 
continuity 
BPH 
  
36 Perumal thevar 61 2904/10 BPH   3cc + + + _ LGPIN - - - 2.1 - 
BPH with 
LGPIN 
37 muniyan 70 2985/10 BPH   4cc + + + - - - - - 1.4 - BPH 
38 Thondhi  70 2986/10 BPH   4cc + + _ _ - - - - 1.5 - BPH 
39 Nagan 70 2987/10 BPH   5cc + + - - - - - - 1.2 - BPH 
40 Chellaiya  73 3222/10 BPH   4cc + + + + - - - - 1.4 - BPH 
41 Appas pillai 60 3245/10 BPH   4cc + + + - LGPIN - - - 2.4 - 
BPH with 
LGPIN 
42 Gopal  60 3246/10 BPH   7cc + + - - - - - - 1.3 - BPH 
43 Krishnan  60 3405/10 BPH   2cc - + - - - - - - 1.2 - BPH 
44 Sankaran  67 3406/10 BPH   3cc + + + - - - - - 1.3 - BPH 
45 Kadhan  65 3665/10 BPH   8cc + + + - - - - - 1.4 - BPH 
46 Puliyan  54 3794/10 BPH   7cc + + _ - - - - - 1.4 - BPH 
47 Pandi  55 3940/10 BPH   7cc + + + _ - - - - 1.4 - BPH 
48 China raj 67 119/11 BPH   4cc + + + + LGPIN - - - 1.9 
P 63 -
Continuous  
BPH with 
LGPIN 
49 Velusamy  72 240/11 BPH   5cc + + + - - - - - 1.5 - BPH 
50 Raj  70 392/11 BPH   2cc + + + - - - - - 1.4 - BPH 
51 Nallakannu  75 520/11 BPH   7cc + + _ - - - - - 1.4 - BPH 
52 Nata rajan 64 521/11 BPH   4cc + + + - - - - - 1.4 - BPH 
53 udayathevar 65 715/11 BPH   6cc + + - - - - - - 1.3 - BPH 
54 madasamy 69 845/11 BPH   4cc + + - - - - - - 1.2 - BPH 
55 pandi 70 847/11 BPH   5cc + + - - - - - - 1.3 - BPH 
56 Rasuthevar 72 892/11 BPH   4cc + + - - - - - - 1.2 - BPH 
57 Radha krishnan 58 29/09 BPH   4cc + + + - - - - - 1.4 - BPH 
58 Ramaraj  60 34/09 BPH   4cc + + + - - - - - 1.4 - BPH 
59 Alagar samy 60 36/09 BPH 14.3ng/ml 7cc + + - - HGPIN - + 1+2 4 
P 63 - 
Absent 
Prostatic 
adeno 
carcinoma 
(1+2)score 3 
  
60 Gandhimathinathan  68 37/09 BPH   8CC + + + - LGPIN - - - 2.4 
P 63 - 
Continuous  
BPH with 
LGPIN 
61 Srinivasan 63 40/09 BPH 2.3ng/ml 7cc + + + - - - - - 1.4 - BPH 
62 Mohan sundar 64 44/09 BPH 3.8ng/ml 6cc + + + - - - - - 1.4 - BPH 
63 Subbaiah  73 47/09 BPH 0.6ng/ml 5cc + + + - - - - - 1.5 - BPH 
64 Arumugam 65 49/09 BPH   6cc + + + - -   - - 1.4 - BPH 
65 Raja gopal 65 50/09 BPH    4cc - - - - HGPIN - + 1+4 4.5 
P 63 - 
Absent 
Prostatic 
adeno 
carcinoma 
(1+4)score 5 
66 Pandiyan  69 59/09 BPH 2.6ng/ml 5cc + + + - - - - - 1.5 - BPH 
67 Chellaiah  71 78/09 BPH 3.3ng/ml 5cc + + + - - - - - 1.4 - BPH 
68 Baskara pandian 57 80/09 BPH 2.2ng/ml 8cc + + + - - - - - 1.4 - BPH 
69 Madasamy   64 102/09 BPH 0.9ng/ml 7cc + + + - - - - - 1.4 - BPH 
70 Sonai muthu 79 110/09 BPH 1.0ng/ml 5cc + + + - - - - - 1.2 - BPH 
71 Subramaniyan 73 111/09 BPH 5.9ng/ml 4cc + + + - - - - - 1.2 - BPH 
72 Rama krishnan 81 008/10 BPH 5.5ng/ml 5cc + + + - -   - - 1.5 - BPH 
73 Rajendran  74 21/10 BPH 11.2ng/ml 4cc _ - + _ - 
Granulo 
matous 
prostatitis 
- - 2.1 
P 63 - Focal 
discontinuity 
Granulo 
matous 
prostatitis 
74 Devaraj  64 32/10 BPH   4cc + + + - -   - - 1.7 - BPH 
75 Velusamy  68 37/10 BPH 8.8ng/ml 5cc + + + - - - - - 1.4 - BPH 
76 Marisamy  68 47/10 BPH   4cc + + + - - - - - 1.4 - BPH 
77 Soundara pandi 61 48/10 BPH 3.7ng/ml 5cc + + + - - - - - 1.4 - BPH 
78 Chinna thambi 56 50/10 BPH 7.1ng/ml 4cc + + - - - - - - 1.3 - BPH 
79 Mari muthu 55 53/10 BPH   5cc + + - - - - - - 1.4 - BPH 
80 Rajendran  65 55/10 BPH 12.9ng/ml 6cc + + + - - - - - 1.4 - BPH 
81 Yesudiam  75 56/10 BPH   7cc + + + - -   - - 1.5 - BPH 
82 Jeya balan 60 57/10 BPH 0.1ng/ml 4cc + + _ - - - - - 1.4 - BPH 
83 Shanmugam  60 58/10 BPH 0.9ng/ml 4cc + + + - - - - - 1.4 - BPH 
84 Muthu raj 75 66/10 BPH 4.2ng/ml 5cc + + - - - - - - 1.4 - BPH 
85 Ramalingam  60 67/10 BPH 4.1ng/ml 4cc + + + - -   - - 1.5 - BPH 
86 Pandian  60 74/10 BPH 1.5ng/ml 4cc + + _ _ - - - - 1.4 - BPH 
  
87 
Karuppana 
kamatchi 
60 76/10 BPH 5.4ng/ml 5cc + + - - LGPIN - - - 2.2 - 
BPH with 
LGPIN 
88 Pitchai  72 78/10 BPH   4cc - - - - - - + 3+2 4.8 - 
Prostatic 
adeno 
carcinoma 
(3+2)score 5 
89 Vellapan  60 81/10 BPH    5cc - - - - - - +     
Desmin - 
positive 
Leiomyo 
sarcoma of 
prostate  
90 Appas ali khan 62 83/10 BPH   4cc + + + - -   - - 1.4 
P 63 - 
Continuous  
BPH 
91 Karuppan  55 85/10 BPH  6.1ng/ml 4cc + + + - -   - - 1.4 - BPH 
92 Solaiah  79 87/10 BPH 0.1ng/ml 4cc + + _ - - - - - 1.4 - BPH 
93 Mariappan  70 90/10 BPH 0.2ng/ml 3cc + + + - - - - - 1.4 - BPH 
94 Rajasekar  65 93/10 BPH 1.3ng/ml 6cc + + + - - - - - 1.4 - BPH 
95 Saleem  53 95/10 BPH 1.4ng/ml 4cc + + + - - - - - 1.4 - BPH 
96 Alagar samy 65 97/10 BPH 0.6ng/ml 4cc + + + - - - - - 1.5 - BPH 
97 Karuppu  66  101/10 BPH   6cc + + - - -   - - 1.7   BPH 
98 Sethu raman  80 103/10 BPH   5cc + + + - HGPIN - - - 3.9 - 
BPH with 
HGPIN 
99 Kesavan  64 106/10 BPH 1.9ng/ml 5cc + + + - -   - - 1.4 - BPH 
100 Abu becker 56 109/10 BPH 1.7ng/ml 5cc + + + - -   - - 1.5 - BPH 
101 Vasu  60 114/10 BPH   6cc + + _ - - - - - 1.5 - BPH 
102 Mahalingam  62 115/10  BPH   6cc + + + - -   - - 1.6 - BPH 
103 Mohammed kasim  72 116/10 BPH   5cc + + - - -   - - 1.5   BPH  
104 
Sundara 
mahalingam  
68 002/11  BPH   6cc + + + - - - - - 1.4 - BPH 
105 Muniyandi thevar  75 004/11 BPH 2.4ng/ml 4cc + + + - - - - - 1.4 - BPH 
106 Srinivasan 60 20/11 BPH   7cc _ - + - - 
Tuberculous 
granulo 
matous 
prostatitis 
- - 1.7 - 
Tuberculous 
granulo 
matous 
prostatitis 
  
107 sampath 65 25/11 BPH 19.1ng/ml 5cc _ _ _ - - - + 2+3 4.9 - 
Prostatic 
adeno 
carcinoma 
(2+3) score 5 
108 subbaiah naicker 77 46/11 BPH 23.2ng/ml 7cc _ _ _ _ - - + 3+4 5.2 - 
Prostatic 
adeno 
carcinoma 
(3+4) score7 
 
ABSTRACT 
 
BACKGROUND 
Interpretation of prostatic biopsies has been a continuous problem 
for practising pathologist. Various types of difficulties have been 
encountered while diagnosing and typing prostatic carcinoma and 
premalignant lesions especially in TURP specimens. 
AIM 
 This current study aims at the analysis of histopathological 
features of various non neoplastic and neoplastic lesions of the prostate 
including the grading of malignant lesions and evaluation of role of basal 
cell and proliferative markers in different benign, premalignant and 
malignant lesions of prostate.  
METHOD 
 One hundred and eight transurethral resection of prostate specimens 
were studied with haematoxylin and eosin and AgNOR staining. In ten 
selected cases immunohistochemical study with p63 was done. 
RESULTS 
BPH was the most common lesion affecting the prostate in elderly 
{96 cases (88.89%)}. The age incidence of Nodular Hyperplasia was high 
in 7
th
 decade Granulomatous prostatitis was rarely encountered {2 cases 
(1.85%)}. HGPIN had high degree of association with prostatic carcinoma 
(25%). Among the malignant lesions of the prostate, primary prostatic 
adenocarcinoma was the commonest (80%). According to Gleason 
Grading system higher grades were more commonly observed as the 
predominant pattern. Mean AgNOR counts (proliferative activity) were 
higher in malignant lesions (4.81) when compared with the benign lesions 
(1.44). With Immunohistochemical staining invasiveness increasesd from 
benign (continuous staining) to malignant (absence of staining) end in the 
spectrum of prostatic lesions. Two rare cases, Leiomyosarcoma of prostate 
and contiguous spread of rectal adenocarcinoma to prostate were observed 
in the present study which were confirmed with immunohistochemical 
study with desmin and PSA respectively. 
CONCLUSION 
 Basal cell markers and proliferative markers have significant 
role in the diagnosis of prostatic lesions especially which fall in the 
premalignant category and which create difficulty in the diagnosis by 
routine histopathological study. 
KEYWORDS 
Benign prostatic hyperplasia, prostatic adenocarcinoma, AgNOR, p63 
